AstraZeneca files patent suit over Crestor

An AstraZeneca PLC unit sued generic drug maker Teva Pharmaceuticals USA alleging infringement of a patent for the anti-cholesterol drug Crestor. AstraZeneca, the U.K.'s second-largest drug maker, said Teva wrongly has applied to the U.S. Food and Drug Administration to market a copy of Crestor before the 2001 patent expires in 2016, according to papers filed Friday in federal court in Delaware. The case is AstraZeneca Pharmaceuticals LP, v. Teva Pharmaceuticals USA, 08CV426, U.S. District Court, Wilmington.